The life sciences sector is at a crossroads as the FDA updates quality management standards. AI is now expected, and the FDA’s January 2025 draft guidance outlines its evaluation and implementation. Successful adoption depends on three key questions.
Safe and Sane: Understanding the FDA’s Risk-Based Approach to AI
Related Posts
Automation Testing for Retail Businesses – Key Considerations
Content 1. What are the Benefits of Automation Testing for Retail businesses? 2. What are the Best Practices…
Ipri-Brown Begins Term as ASME’s 143rd President, New Members and Nominees to the Board of Governors Announced
Susan Ipri-Brown has begun her term as the 143rd president of the American Society of Mechanical Engineers (ASME),…
Basic Concepts to Applying Quality 4.0
Quality 4.0 looks at how digitization improves industry processes. Despite over 10 years of focus, there’s still no…